: Because of the relevant importance of the IL-33/ST2 axis in COPD pathobiology, the future results of AERIFY-1 and AERIFY-2 trials could disclose new information about subgroups of responder patients to biologic therapies for this highly prevalent disease https://bit.ly/3USJCUP.
Interleukin 33: a suitable target for biological therapies of COPD?
Pelaia, Corrado
2024-01-01
Abstract
: Because of the relevant importance of the IL-33/ST2 axis in COPD pathobiology, the future results of AERIFY-1 and AERIFY-2 trials could disclose new information about subgroups of responder patients to biologic therapies for this highly prevalent disease https://bit.ly/3USJCUP.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
